Результаты поиска

Endometriosis and chronic pain: a multispecialty roundtable discussion.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Endometriosis: translation of molecular insights to management.

Endometriosis is a debilitating gynecologic disorder causing pelvic pain and infertility and characterized by the implantation of endometrial tissue to extrauterine locations. Though aspects of the condition remain enigmatic, the molecular pathophysiology of endometriosis appears to be clarifying. Estrogen dependence of the disease is a sentinel endocrine feature and reduction of estrogen bioavailability is the therapeutic principle upon which traditional treatment and prevention approaches have been based. Endometriosis is a chronic inflammatory condition associated with lesional neoangiogene

Полнотрансформатная ретиноидальная кислота в гематологическое расстройство: не только острая промиелоцитическая лейкемия.

Всетранс-ретиноиновая кислота (ATRA) играет определенную роль в развитии тканей, нейронной функции, воспроизводстве, зрение, росте и дифференциации клеток, иммунитете от опухоли и апоптозе. АТРА может действовать, вызывая автофагическую сигнализацию, ангиогенез, клеточную дифференциацию, апоптоз и иммунную функцию. В крови ATRA впервые с большим успехом использовалась в острой промиелоцитической лейкемии (APL), где ATRA дифференцировала клетки лейкемии на зрелые гранулоциты. АТРА может играть определенную роль не только в ППН, но и в других гематоологических заболеваниях, таких, как иммунная т

Совпадение в полном тексте источника
… The study by Feng FE et al. ( Feng FE. et al., 2017 ) randomly assigned ITP patients in a 1:1 ratio to receive either oral ATRA (10 mg bid) + oral danazol (200 mg bid) or oral danazol monotherapy (200 mg bid) for 16 weeks 45 patients were enrolled in the ATRA + danazol group, and 48 in the danazol group … . 28 patients (62%) treated with ATRA + danazol achieved a sustained response compared with 12 patients (25%) in the danazol monotherapy group, a statistically significant difference between the two groups. …

Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.

Livedoid vasculopathy (LV) is a rare, chronic, and occlusive disease of the veins supplying the upper parts of the skin. The pathogenesis of the disease is not precisely understood, and its attacks are often unpredictable but tend to worsen during the summer. LV affects women more often. This increased risk for LV in women might be related to sex-specific physiological conditions, such as pregnancy, or a higher incidence of LV-associated conditions, such as connective tissue diseases, hypercoagulable states, and venous stasis in women. The typical clinical appearance of LV consists of three ma

Совпадение в полном тексте источника
… Response to low-dose danazol Arch Dermatol 132 1996 749 751 8678566 10.1001/archderm.1996.03890310027003 Hsiao GH Chiu HC. Low-dose danazol in the treatment of livedoid vasculitis Dermatology 194 1997 251 255 9187843 10.1159/000246113 Hsiao PF Wu YH. … Fibrinolysis induced by danazol Blut 53 1986 351 352 3756360 10.1007/BF00320896 Rujitharanawong C Chularojanamontri L Trakanwittayarak S Pinkaew S Nuttawong S. …

Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature.

BackgroundImmune-mediated cytopenias (AIC) are challenging complications following allogeneic hematopoietic stem cell transplantation (HSCT). While broad-acting immunosuppressive agents like corticosteroids are often standard of care, several novel therapies which target specific immunological pathways have recently been developed and provide hope for patients with steroid-refractory courses and may limit long-term toxicity. The successful off-label use of the plasma cell depleting anti-CD38 antibody daratumumab was published in several case reports, suggesting efficacy, i.e., in patients with

Совпадение в полном тексте источника
… (just danazol concomintant) Table 1 Clinical summary of twelve patients with autoimmune cytopenia following stem cell transplantation who received therapy with daratumumab Abbreviations : AIC Immune-mediated cytopenia (allo- or autoimmune cytopenia), AIHA Allo- or autoimmune hemolytic anaemia, AIT … (just danazol concomintant) Discussion and conclusions AIC is a challenging complication following allogeneic HSCT, mostly occurring in patients with a non-malignant primary disease [ 13 , 14 ]. …

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada.

BackgroundHereditary angioedema (HAE) is a rare autosomal dominant disease resulting in recurring episodes of swelling, leading to considerable patient morbidity and mortality. Lanadelumab is a plasma kallikrein inhibitor that is approved as 1st line therapy in Canada for long term prophylaxis of HAE attacks.ObjectiveTo describe our clinical findings from a case series of adult patients with HAE type 1/2 who have been initiated on lanadelumab.MethodsA chart review of HAE type 1/2 patients at three academic centers in Canada was undertaken with demographic and clinical data extracted. Patients

Совпадение в полном тексте источника
… Available second line options for LTP in some patients include attenuated androgens such as danazol and tranexamic acid (TXA), an antifibrinolytic [ 3 ]. … C1-INH 4500U SC q3-4d C1-INH IV May 2019 300 mg SC q2w C1-INH IV 11 Lip swelling Abdominal pain Laryngeal swelling Laryngeal swelling TXA C1-INH 1500U IV q2-3d Icatibant or C1-INH IV January 2020 300 mg SC q2w Icatibant or C1-INH IV 12 Abdominal pain Laryngeal swelling Abdominal, Laryngeal Danazol C1 …

Management of immune thrombocytopenic purpura in adults.

Primary immune thrombocytopenic purpura (ITP), also referred to as idiopathic thrombocytopenic purpura, is an organ-specific autoimmune disorder in which antibody-coated or immune complex-coated platelets are destroyed prematurely by the reticuloendothelial system, resulting in peripheral blood thrombocytopenia. The disease is heterogeneous with regard to its severity and clinical course and is unpredictable in its response to therapy. Although the basic underlying pathophysiology of ITP has been known for more than 50 years, current treatment guidelines are based on expert opinion rather than

Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities.

Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis are adverse hypersensitivity reactions that affect the skin and mucous membranes. They are characterised by erythematous macules and hemorrhagic erosions of the mucous membranes. Epidermal detachments of varying degrees of severity also occur in these conditions. Various aetiologies are associated with these conditions, with adverse drug reaction being the most common. Though the worldwide incidence of these conditions is recorded as low, diverse types of medication are being observed to lead to these conditions. This review compiles in

Совпадение в полном тексте источника
… Androgenic hormones Danazol: A patient diagnosed with systemic lupus erythematosus was prescribed danazol for treatment of autoimmune hemolytic anaemia. It has been approved as a second line agent in SLE related haematological disorders including thrombocytopenia [ 56 ]. … Androgenic anabolic steroids: An athlete involved in the illicit use of steroids presented with SJS immediately after injecting drostanolone propionate, danazol, and metenolone enanthate [ 57 ]. …

Новое применение XPO1 для лечения миэлофиброза.

Myelofibrosis (MF) — новообразование, характеризующееся конституционными симптомами, прогрессивными цитопентиями и селеногамели. В основе патобологии MF лежит активация мутации на пути JAK/STAT и регулирование цитокинового костного мозга. Хотя многие ингибиторы JAK в настоящее время официально утверждены и обеспечивают значительное улучшение симптомов, эти агенты не имеют курса на изменение потенциала. Кроме того, результаты являются неудовлетворительными для пациентов, которые не справляются с ингибиторами JAK, что подчеркивает необходимость применения новых методов лечения, основанных на исп

Совпадение в полном тексте источника
… . 24 The trial met its primary end point of improvement in MF-related total symptom score (TSS), but, more importantly, hemoglobin stabilization and rate of transfusion independence at week 24 in the momelotinib treatment group were statistically noninferior to that of the danazol group. 24 Furthermore … , although transfusion independence rates were noninferior at week 24 (30% in the momelotinib arm compared with 20% in the danazol arm), transfusion independence rates at week 48 were 57% in those who continued on momelotinib and 60% in those who crossed over from the danazol arm. 25 Similarly, pacritinib …

Autoimmune Progesterone Dermatitis Diagnosed by Lymphocyte Transformation Test and Progesterone Provocation Test.

Autoimmune progesterone dermatitis (APD) is rare autoimmune response to endogenous progesterone or to earlier exposure to exogenous progeste … contain a progesterone component. If this treatment is ineffective, patients have been treated with danazol, gonadotropin releasing hormone analogs (3,4,6), conjugated estrogens (7), tamoxifen, oophorectomy (8), and progestogen desensitization (10) with varying success.

Therapeutic Approaches for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: Current and Emerging Strategies.

Human T-cell leukemia virus-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic inflammatory disease of the spinal cord induced by immunological activation due to high HTLV-1 proviral load in the peripheral blood. HAM/TSP is representative of HTLV-1-related inflammatory diseases, and its main neurological symptoms-namely, motor dysfunction of the lower extremities through spastic paraparesis with urinary disturbance-are progressive and lead to deterioration in the quality of life of patients once these dysfunctions develop. Therefore, novel and safe therapeutic

Совпадение в полном тексте источника
… Danazol 14. L-Arginine The search methodology We performed a targeted search of PubMed until March, 2026. The search strategy included the following keywords: HTLV-1, HAM, HAM/TSP, and Treatment. The search was limited to articles published in the English language. … Danazol The efficacy of danazol, which is a derivative of testosterone, as a treatment for HAM/TSP patients has been reported in a placebo-controlled trial [ 62 ]. …

Romiplostim as a treatment for immune thrombocytopenia: a review.

"Immune thrombocytopenia" (ITP) is an autoimmune disorder that leads to peripheral destruction, as well as a decreased production of platelets. ITP most commonly presents as mild mucocutaneous bleeding. Though it is rare, the leading cause of mortality in persons with ITP is intracranial hemorrhage and those that do not respond to therapy are at increased risk. Our understanding of the pathophysiology of ITP has evolved immensely, especially over the last 60 years. The discovery of the platelet-production stimulator, thrombopoietin (TPO), lent clarity to an earlier hypothesis that inhibition o

Совпадение в полном тексте источника
… Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. Haematologica. 1993;78(6 Suppl 2):29–34. 27. … Danazol for children with immune thrombocytopenic purpura. Am J Dis Child. 1988;142(12):1317–1319. doi: 10.1001/archpedi.1988.02150120071043. 31. Marwaha RK, Singh RP, Garewal G, Marwaha N, Prakash D, Sarode R. Colchicine therapy in immune thrombocytopenic purpura. …

Distinctive and common features of moderate aplastic anaemia.

The therapy algorithm for severe aplastic anaemia (sAA) is established but moderate AA (mAA), which likely reflects a more diverse pathogenic mechanism, often represents a treatment/management conundrum. A cohort of AA patients (n = 325) was queried for those with non-severe disease using stringent criteria including bone marrow hypocellularity and chronic persistence of moderately depressed blood counts. As a result, we have identified and analyzed pathological and clinical features in 85 mAA patients. Progression to sAA and direct clonal evolution (paroxysmal nocturnal haemoglobinuria/acute

Consensus guidelines for the management of chronic pelvic pain.

OBJECTIVE: To improve the understanding of chronic pelvic pain (CPP) and to provide evidence-based guidelines of value to primary care healt … treatment of chronic pelvic pain of gynaecologic origin, including oral contraceptives, progestins, danazol, and gonadotropin-releasing hormone agonists, has been studied extensively and should be considered as the first line for many women, especially those with endometriosis (I and II-1A). 3. Adjuvant medications, such as antidepressants and antibiotics …

Identification of Fatty Acid Metabolism Disorder-Related Gene Signature in Septic Cardiomyopathy.

Evans syndrome (ES) is a rare condition, defined as the presence of 2 autoimmune cytopenias, most frequently autoimmune hemolytic anemia and immune thrombocytopenia (ITP) and rarely autoimmune neutropenia. ES can be classified as primary or secondary to various conditions, including lymphoproliferative disorders, other systemic autoimmune diseases, and primary immunodeficiencies, particularly in children. In adult ES, little is known about clinical features, disease associations, and outcomes. In this retrospective international study, we analyzed 116 adult patients followed at 13 European ter

Совпадение в полном тексте источника
… Additional frontline treatments in primary refractory cases (23%) comprised rituximab (n = 10), immunosuppressants (n = 8), splenectomy (n = 3), danazol (n = 3), TPO-RAs (n = 2), and PEX (n = 1). … Finally, a minority of patients (8%) received other treatments, including danazol (n = 5), PEX (n = 2), recombinant erythropoietin (n = 1), and the oral phosphatidylinositol 3-kinase inhibitor parsaclisib in a clinical trial (n = 1). …

Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis.

We report here the results of therapeutic trials in 200 patients with HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) conducted in our department between 1986 and 1993. Motor disability grades were improved by more than one grade in 69.5% (91/131) of patients by oral administration of prednisolone, 50% (3/6) by eperisone hydrochloride only, 43.8% (7/16) by blood purification (lymphocytapheresis and plasmapheresis), 40.0% (2/5) by intrathecal injection of hydrocortisone, 30.0% (3/10) by intravenous injection of high-dose methylprednisolone, 23.3% (10/43) by interferon-alph

Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.

AbstractAutoimmune hemolytic anemia (AIHA) is a rare autoantibody-mediated disease. For steroid and/or rituximab-refractory AIHA, there is no consensus on optimal treatment. Daratumumab, a monoclonal antibody targeting CD38, could be beneficial by suppression of CD38+ plasma cells and thus autoantibody secretion. In addition, because CD38 is also expressed by activated T cells, daratumumab may also act via immunomodulatory effects. We evaluated the efficacy and safety of daratumumab monotherapy in an international retrospective study including 19 adult patients with heavily pretreated refracto

Совпадение в полном тексте источника
… C<2+ | Evans syndrome | - | Steroids, rituximab | Steroids | 10.7 | 24 | 335 | - 8 | 42/M | wAIHA DAT IgG>2+ and C<2+ | Evans syndrome, MGUS IgG kappa Nonclonal CD8 T-cell proliferation, T-LGL suspect | - | Steroids, rituximab , splenectomy, plasmapheresis, cyclophosphamide, sirolimus, cyclosporin, danazole … , methotrexate | Steroids Sirolimus Plasmapheresis | 4 | 140 | 4800 | 30 9 | 25/F | wAIHA DAT IgG>2+ | Evans syndrome | - | Steroids, rituximab, IVIG, bortezomib, sirolimus, danazol, EPO | Danazol Sirolimus | 6.3 | 19 | 421 | - 10 | 59/M | wAIHA DAT>2+ IgG | IgG MGUS | - | Steroids, rituximab IVIG, EPO …

Gynaecological and obstetric management of women with inherited bleeding disorders.

OBJECTIVE: The prevalence of bleeding disorders, notably von Willebrand disease (vWD), among adult women with objectively documented menorrh … to hormonal therapy (oral contraceptives [II-1B], depot medroxyprogesterone acetate (DMPA) [II-3B], danazol [II-2B], GnRH analogs [II-3B]) or local treatments (levonorgestrel-releasing IUS [II-1B]) and non-hormonal therapy (antifibrinolytic drug tranexamic acid [II-1B]) as well as desmopressin (II-1B). These therapies represent first line treatment. Blood …

Gynaecological and obstetric management of women with inherited bleeding disorders.

OBJECTIVE: The prevalence of bleeding disorders, notably von Willebrand disease (vWD), among adult women with objectively documented menorrh … to hormonal therapy (oral contraceptives [II-1B], depot medroxyprogesterone acetate (DMPA) [II-3B], danazol [II-2B], GnRH analogs [II-3B]) or local treatments (levonorgestrel-releasing IUS [II-1B]) and non-hormonal therapy (antifibrinolytic drug tranexamic acid [II-1B]) as well as desmopressin (II-1B). These therapies represent first line treatment. Blood …

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

BACKGROUND: Immune thrombocytopenia is an autoimmune bleeding disorder. Daratumumab, a human monoclonal antibody targeting CD38 glycoprotein, is currently under clinical investigation as a potential therapy for autoimmune diseases. This trial aimed to evaluate the efficacy and safety of daratumumab in adults with immune thrombocytopenia. METHODS: This single-center, open-label, phase 2 trial enrolled patients with a platelet count <30 × 109 platelets per L during the screening period. The study protocol comprised a 4-week screening phase, an 8-week treatment course, and a 16-week follow-up pe

Совпадение в полном тексте источника
… (%) | 63 (100.0) Recombinant human thrombopoietin | 47 (74.6) Thrombopoietin receptor agonists | 63 (100.0) Anti-CD20 monoclonal antibody | 20 (31.8) Rituximab | 19 (30.2) Obinutuzumab | 1 (1.6) Splenectomy | 3 (4.8) Immunosuppressive agents | 18 (28.6) Cyclosporine | 16 (25.4) Sirolimus | 4 (6.3) Danazol … positive | 4 (6.3) Double positive | 13 (20.6) Negative | 22 (34.9) Common previous therapeutic regimens included glucocorticoids (n = 63 [100%]), IVIg (n = 68 [92%]), thrombopoietic agents (n = 63 [100%]), anti-CD20 monoclonal antibodies (n = 20 [31.8%]), immunosuppressive agents (n = 18 [29%]), danazol …